Categories: DevelopmentDrugScience
We are a precision oncology company pioneering the development of cancer therapies guided by functional genomics. We develop treatments for patients with genetically defined cancers, whose current treatment options are limited. A UNIQUE APPROACH To address the unmet needs of a diverse patient population, we’ve developed unique AI-supported drug discovery methods that accurately identify oncogenic […]
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.04.2018 | - | $6M | - |
Mentions in press and media 3
| Date | Title | Description |
| 01.05.2018 | Term Sheet — Tuesday, May 1 | A TALE OF TWO COMEBACKS
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
Seven months later, he’s back for his second act with a new blockchain-focused (surprise!) startup that helps exped... |
| 30.04.2018 | NovellusDx Announces It Has Completed an Equity Financing of $6 Million | Jerusalem, Israel, 30 April 2018 – NovellusDx, the leader in functional genomics, today announced it has completed an equity financing of $6 million. The financing round is with the participation of Helsinn Investment Fund S.A. SICAR, par... |
| 30.04.2018 | NovellusDx Completes $6M Equity Financing | NovellusDx, a Jerusalem, Israel-based functional genomics company, completed a $6m equity financing.
Backers in the round, which adds to the nearly $17m already raised, included Helsinn Investment Fund S.A. SICAR, part of Helsinn Group, a c... |
Reviews 0
